ABSTRACT INTRODUCTION: Eye symptoms are comparatively frequent in the clinical evidence of Basedow's disease in childhood. Severe forms of thyroid-associated ophthalmopathy are casuistic in pediatric patients. Early diagnose and evaluation of the severity of thyroid orbitopathy and relevant specialist treatment are key prognostic factors according to the contemporary consensuses. AIM: The aim of the present study was to make a review of the contemporary diagnostic and therapeutic abilities in pediatric patients with Basedow's disease and thyroid-associated ophthalmopathy. We present a clinical case of severe TAO in an 11-year-old girl with Basedow's disease. The combined therapeutic scheme based on the EUGOGO (European Group on Graves' orbitopathy) consensus of 2008 includes not only thyrostatics but also local ophthalmic agents and pulse corticosteroid therapy, followed by an alternating dose regimen. The favourable outcome of the treatment is determined to a great extend by the close collaboration between the pediatric endocrinologist and the ophthalmologist. CONCLUSION: It is concluded that children with thyroid-associated ophthlmopathy should promptly be referred to a specialized centre for evaluation of the severity of orbitopathy and an adequate therapy. This is of crucial importance for the preservation of patient's sight.
INTRODUCTION
Thyroid gland diseases are the second most frequent endocrinopathies in childhood after diabetes and the condition of hypothyroidism is the prevailing one. The serious effects on the intellectual development of the child when the diagnose of congenital hypothyreosis is delayed make it very necessary to have specialized knowledge and examination. 1, 2 Far rarer in childhood are the disorders with hyper-function of the thyroid gland, in particular Basedow's disease. Because of that and in view of the more untypical course of the disease in children, Basedow's disease is usually not considered, all the more that the initial symptoms may be non-specifi c and are often related to the characteristics of puberty when the disease fi rst appears usually. 3 The incidence of Basedow's disease in childhood varies within wide limits as reported by different studies. In the USA, for example, approximately 10% of the children born to mothers with Basedow's disease had elevated levels of the thyroid hormones, but only 1-2% had clinical evidence of hyper-thyroidism. A Dutch study reported that the national annual incidence of thyreotoxicosis in 0-14 years children was 0.79 per 100 000. The maximum frequency was in the age group from 10 to 14 years. 4 Marked differences in the incidence of the disease were found for the various countries and ethnic groups. A recent study in Hong Kong for example documented an incidence of 6.5 per 100 000 Chinese children. 5 Except for the cases of neonatal hyperthyroid- ism, which are extremely rare, thyreotoxicosis in late childhood is usually a manifestation of the autoimmune disorder Basedow's disease. It is characterized by diffuse enlargement of the thyroid gland, hyperthyroidism and, not so rarely, by ophthalmopathy. The pathogenesis of the disease is associated with the production of antibodies against TSHR -the TSH receptor of the thyroid gland cells. The reasons for the ophthalmopathy are not clarifi ed to the full, but it is supposed that there is a cross-reactivity of the circulating antibodies against the thyroid antigens with the antigens of the orbital and extra-orbital tissues (particularly the orbital preadipocyte fi broblasts and the retro-orbital muscle antigens). The varied clinical evidence of thyroid-associated ophthalmopathy (TAO) depends on the main tissue damage. The orbital cytokines produced by the antigen-stimulated T-Ly and by the fi broblasts play a key role in the pathogenesis of ophthalmopathy. 6, 7 The severity of TAO in childhood is smaller in comparison with adults. Severe forms of the disorder are mostly found in adolescent patients, and modern studies have defi nitely proved the key role of smoking, which becomes more frequent in that period of life. Even passive smoking alone is a risk factor. The incidence of TAO is greater in countries where smoking is more popular among the adolescent population. One European study reported TAO in 33% of the pediatric patients with Basedow's disease. 8 Over the last 5 years, 15 children with Basedow's disease with clinical and laboratory evidence have been hospitalized at the Clinic of Pediatric and Genetic Diseases in Plovdiv. Eleven of our patients had eye symptoms of various severity ranging from mild exophthalmos to ТАО. Two of the children had to undergo a high-dose continuous treatment of the ophthalmopathy. Our detailed literature survey, the good results we obtained and the comparatively poor experience of pediatric endocrinologists in the treatment of this rare complication were the cause to present one of these cases.
In the present article we demonstrate a case of an 11-year-old girl with Basedow's disease and severe form of ТАО. The timely diagnose and the adequate treatment received by the patient in accordance with the modern consensuses was of crucial importance for the favourable outcome for the patient. 
CASE DESCRIPTION
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DISCUSSION
Because of the comparatively low incidence of Basedow's disease in children the correct diagnose of the disease is often late for several months. The usual alarming symptom to ask for help is poor concentration which results in certain problems with the school rates and patients usually are referred to different specialists -psychologists, neurologists and psychiatrics. Only after the appearance of more specifi c symptoms -enlarged thyroid gland, constant tachycardia, palpitations, fatigability, reduced tolerance to physical activity, increased intestinal peristalsis and nycturia, the diagnose becomes available. 9 Basedow's disease is often associated with eye symptoms as well -thyroid-associated ophthalmo- Severe sight-threatening form -with involvement of the optic nerve (DON-Dysthyroid Optic Neuropathy) and/or the cornea (ulcerations). This category warrants immediate treatment with pulseMethylprednisolone -MPS, usually followed by treatment with oral corticosteroids (CS). If there is no signifi cant improvement of DON after 1-2 weeks, the pulse dose should be repeated, and, if necessary, surgical decompression of the orbit should be carried out.
Moderate form -it is characterized by one or several of the following manifestations -eyelid retraction ≥ 2 mm, involvement of the periorbital soft tissues -edema, conjunctival injection, chemosis, proptosis ≥ 22 mm after Hertel for the Caucasian race; inconstant -in some directions or constant -in all directions diplopia. Initiation of CS therapy is determined by the activity of the process which is assessed by a point system -the so called CAS (clinical activity score). Telegammatherapy is not indicated in childhood. In non-active forms or cases of stabilized active moderate forms as a result of the CS treatment some rehabilitatative surgical interventions may become necessary -corrections of the diplopia, of the palpebral fi ssure width, blepharoplasty or decompressive orbitotomy after a six-month period of inactivity. 10, 5 Mild form -with one or more of the following manifestations -irritation, tearing, photophobia, mild eyelid retraction (< 2 mm), mild manifestations on behalf of the periorbital soft tissues, proptosis < 22 mm after Hertel, transient diplopia -only at tiredness or at waking-up. In such cases only the general standards are applied and some rehabilitation surgical interventions may become necessary (Fig. 1) .
The clinical case presented by us was classifi ed as a severe form of TAO and that defi ned our choice of treatment.
Basedow's disease rarely undergoes spontaneous remission, which means that treatment is usually indispensable. Three methods are promoted nowadays including thyrostatics for oral administration, radioiodtherapy and surgical treatment. When TAO is diagnosed and its grade of severity is defi ned correctly specifi c treatment for the ophthalmopathy is applied parallel with the already chosen thyrostatic treatment. 9 There are various schemes of pulse-therapy and supporting CS treatment:
Pulse-therapy -with methylprednisolone (MPS) is applied in different schemes according to the different studies:
• MPS -250-1000 mg/24 hours for 3 to 5 successive days depending on the severity of the condition • MPS -7.5-15 mg/kg/24 hours twice a day, every other day, in 2-week intervals, for a period of 2-3 months • MPS -500 mg i.v., once a week for a period of 6 weeks, followed by 250 mg i.v. once a week for another 6 weeks. The total cumulative dose of MPS should not exceed 8 g in the course of treatment. The effectiveness of pulse therapy is 60-8 % and the risk of side effects is smaller compared to the risk of initial schemes of oral CS whose effectiveness does not exceed 50%. As there exist a risk of exacerbation of the process if the high dose and continuous CS treatment is suspended it is recommended recently to apply moderate pulse doses -250-500 mg MPS/24 hours.
Oral corticosteroid treatment -prednisolone or dehydrocortisone • Initial dose of 1 mg/kg/24 hours during the fi rst week followed by reduction of the daily dose to • Initial dose of 40-60 mg/24 hours, gradual reduction of the dose in intervals of 7-14 days to a supporting dose of 15 mg once a day -for a total of 4 to 6 months or more depending on the effect. Method of combined treatment -it is more effective compared to the conventional one and with a lower risk of corticosteroid dependence and side effects.
• Pulse therapy with MPS followed by alternating doses of prednisolone 20-30 mg taken only once every second day, for a period of 4 to 8 months. On the background of the alternating therapy pulse doses of MPS may be also applied -in intervals of 1 to 3 months depending on the effect.
• The most severe cases are subjected to a threestep therapeutic scheme -pulse MPS, conventional doses of prednisolone for a period of up to 6 weeks and doses of 15-20-30 mg/24 hours, followed by alternating therapy: 3 days pulse therapy with MPS, 6 weeks conventional dose of prednisolone, 3 months alternating therapy -prednisolone every 48 hours. Alternative treatment: • In severe forms with no effect of the medicinal treatment -total ablation of the thyroid gland • Somatostatin analogues -only after somatostatin receptors are proved by octreotide scintigraphy • Cytokine-antagonists, including pentoxiphilin • Antioxidants -alupurinol and nikotinamide, selenium agents • NSAID (non-steroid anti-infl ammatory drug) -COX2 -inhibitor • Immunosuppressors -cyclosporine, methotrexate.
CONCLUSIONS
Basedow's disease may occur in childhood albeit comparatively rarely. The severe form of its complication -thyroid-associated ophthalmopathy, is а casuistic rarity in children. The prompt referring of TAO patients to specialist centers of pediatric endocrinology is of crucial importance for the prognosis. Early diagnose of TAO and defi ning its grade of severity should be performed by an experienced team of an ophthalmologist and a pediatric endocrinologist. The complex and adequate treatment based on the contemporary consensuses is a determinant factor for the preservation of the sight of the affected children.
